GE and Global Good sign li­cens­ing deal for malaria di­ag­nos­tics

BioSpectrum (Asia) - - Supplier News -

GE and Global Good Fund have en­tered a li­cens­ing deal with di­ag­nos­tics tech­nol­ogy de­vel­oper Ac­cess Bio for the man­u­fac­ture and dis­tri­bu­tion of new rapid di­ag­nos­tic tests (RDTs) to de­tect asymp­to­matic malaria in low-re­source re­gions.

Co-de­vel­oped by GE Global Re­search Cen­tre and Global Good, the new malaria di­ag­nos­tic tech­nolo­gies are ex­pected to aid in the global elim­i­na­tion of the dis­ease. Formed as a re­sult of an al­liance be­tween In­tel­lec­tual Ven­tures and Bill Gates, Global Good fo­cuses on the in­ven­tion of tech­nol­ogy to im­prove the qual­ity of life in low and mid­dle-in­come coun­tries.

The move is part of

GE’s strat­egy to drive its com­mer­cial­i­sa­tion through in­no­va­tion and growth with part­ners. In ad­di­tion to a sen­si­tive di­ag­nos­tic test to iden­tify key pro­teins in malaria and Plas­mod­ium lac­tate de­hy­dro­ge­nase (pLDH) RDT for de­tec­tion of the malaria par­a­site, the agree­ment cov­ers a tech­nol­ogy for the cre­ation of malaria serol­ogy tests for Plas­mod­ium an­ti­bod­ies to mea­sure past dis­ease ex­po­sure. Ac­cess Bio be­lieves that these tests will be the next gen­er­a­tion of di­ag­nos­tic test­ing and a big step to­wards the erad­i­ca­tion of malaria.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.